We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

64 hedge funds and large institutions have $948M invested in Stoke Therapeutics in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

180% more capital invested

Capital invested by funds: $339M → $948M (+$609M)

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

53.6% more ownership

Funds ownership: 48.7% → 102.3% (+54%)

21% more funds holding

Funds holding: 53 → 64 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
64
Holders Change
+11
Holders Change %
+20.75%
% of All Funds
1.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
27
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.56M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$4.97M
3
RI
RTW Investments
New York
+$4.75M
4
Victory Capital Management
Victory Capital Management
Texas
+$4.42M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.8M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.44M
2
OAM
Oxford Asset Management
United Kingdom
-$2.5M
3
SFM
Sphera Funds Management
Israel
-$2.26M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$1.24M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$647K
Name Holding Trade Value Shares
Change 		Change in
Stake
ALSV
1
ATP Life Science Ventures
New York
$475M +$422M +16,786,713 New
RI
2
RTW Investments
New York
$100M +$4.75M +188,782 +6%
GGHC
3
Gilder Gagnon Howe & Co
New York
$51.7M -$1.24M -49,301 -3%
CAM
4
Cormorant Asset Management
Massachusetts
$50.7M +$6.26K +249 +0%
RCM
5
RA Capital Management
Massachusetts
$31.7M – – –
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$31.7M -$647K -25,735 -2%
RG
7
Redmile Group
California
$28.9M +$83K +3,300 +0.3%
BlackRock
8
BlackRock
New York
$26M +$7.56M +300,663 +49%
Federated Hermes
9
Federated Hermes
Pennsylvania
$21.9M +$4.97M +197,417 +34%
Vanguard Group
10
Vanguard Group
Pennsylvania
$21.9M +$2.5M +99,220 +15%
PA
11
Perceptive Advisors
New York
$19M – – –
Fidelity Investments
12
Fidelity Investments
Massachusetts
$15.7M +$2.8M +111,384 +25%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$13.8M +$2.67M +106,200 +28%
Millennium Management
14
Millennium Management
New York
$9.13M -$9.44M -375,430 -54%
SFM
15
Sphera Funds Management
Israel
$7.26M -$2.26M -90,000 -26%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$5.3M +$1.06M +42,325 +29%
Victory Capital Management
17
Victory Capital Management
Texas
$5.09M +$4.42M +175,735 +4,491%
State Street
18
State Street
Massachusetts
$4.81M +$774K +30,765 +22%
American Century Companies
19
American Century Companies
Missouri
$4.06M +$1.37M +54,572 +61%
CC
20
Casdin Capital
New York
$3.68M – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.39M +$175K +6,965 +6%
Northern Trust
22
Northern Trust
Illinois
$3.33M +$239K +9,508 +9%
Goldman Sachs
23
Goldman Sachs
New York
$1.93M +$548K +21,786 +47%
Charles Schwab
24
Charles Schwab
California
$1.5M +$13.7K +546 +1%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$954K +$229K +9,086 +37%
1
2 3

STOK Hedge Fund Activity: Q4 2019 in Review

64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2019, worth a combined $948M — up 180% from $339M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new STOK positions and 4 closed out — a net gain of 11 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $7.56M. The largest seller was Millennium Management, cutting an estimated $9.44M.

  • 64 institutional investors held Stoke Therapeutics (STOK) as of Q4 2019, up from 53 in Q3 2019.
  • Funds reported $948M of Stoke Therapeutics stock for Q4 2019, up 180% quarter-over-quarter.
  • 15 funds opened new Stoke Therapeutics positions in Q4 2019 and 4 closed out, a net change of +11 holders.
  • The largest Stoke Therapeutics buyer in Q4 2019 was BlackRock, an estimated $7.56M added.
  • The largest Stoke Therapeutics seller in Q4 2019 was Millennium Management, an estimated $9.44M sold.

Based on aggregated 13F filings for Q4 2019.